Effects of the H <sub>2</sub> -Receptor Antagonist Famotidine on the Pharmacokinetics of Atazanavir-Ritonavir With or Without Tenofovir in HIV-Infected Patients
Xiaodong Wang(Baoding People's Hospital), Richard Bertz(Bristol-Myers Squibb (Germany)), Angela D. M. Kashuba(University of North Carolina at Chapel Hill), Michael Child(Bristol-Myers Squibb (Germany)), Pablo Tebas(University of Pennsylvania), Jenny Zhang(Pfizer (United States)), Yaoshi Wu(Bristol-Myers Squibb (Germany)), Li Zhu(Bristol-Myers Squibb (Germany)), Ellen Chung(Bristol-Myers Squibb (Germany)), Marta Boffito(Chelsea and Westminster Hospital NHS Foundation Trust), Kristine B. Patterson(University of North Carolina at Chapel Hill), Lisa Mahnke(Merck Serono S.p.A. (Italy))
Cited by 18
Related Papers
Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy
|Nature|2012|1.2k
Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGFβ, in Advanced Solid Tumors
|Clinical Cancer Research|2018|415
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
|Science Translational Medicine|2011|352